ALLO Jun 2024 5.000 put

OPR - OPR Delayed price. Currency in USD

Add to watchlist

2.2500

+0.2500

(+12.50%)

At close: 03:53PM EDT

Loading interactive chart…

Zacks
Allogene (ALLO) Q1 Earnings in Line With Estimates, Sales Lag
Allogene (ALLO) reports drab first-quarter 2024 results. The company secures the development and marketing rights to its CD19 oncology program in Europe.
GuruFocus.com
Allogene Therapeutics Inc (ALLO) (Q1 2024) Earnings Call Transcript Highlights: Strategic ...
Exploring Allogene's Q1 performance, strategic initiatives in oncology, and financial maneuvers amidst a challenging landscape.
Zacks
Allogene Therapeutics (ALLO) Reports Q1 Loss, Lags Revenue Estimates
Allogene Therapeutics (ALLO) delivered earnings and revenue surprises of 0% and 47.62%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?